Use of Human Chronic Myeloid Leukemia Cells to Study Graft-Versus-Leukemia Immunity in a Xenogeneic Mouse Model of Graft-Versus-Host Disease.

Chloe Sligar, Nicolas R Tomasiello, Peter Cuthbertson, Taylor L Nelson, Amal Elhage, Ronald Sluyter, Debbie Watson

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chloe SligarMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia. csligar@uow.edu.au.ORCID https://orcid.org/0000-0002-9214-0742

Nicolas R TomasielloMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID https://orcid.org/0009-0005-7251-1031

Peter CuthbertsonMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID https://orcid.org/0000-0003-2903-2586

Taylor L NelsonMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID https://orcid.org/0009-0003-6670-895X

Amal ElhageMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID https://orcid.org/0000-0003-0625-3183

Ronald SluyterMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID https://orcid.org/0000-0003-4909-686X

Debbie WatsonMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID https://orcid.org/0000-0002-6242-3944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Humanized mouse models of graft-versus-host disease (GVHD) primarily focus on treatments to prevent disease progression. However, there is little investigation into whether graft-versus-leukemia (GVL) immunity is retained following these treatments for GVHD. Here, we describe the methods to generate a humanized mouse model to study GVL immunity against firefly luciferase (luc) expressing human K562 chronic myeloid leukemia cells in humanized NOD-scid-IL2Rγ

Indexed as

Graft vs Host DiseaseGraft vs Leukemia EffectLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAnimalsDisease Models, AnimalFlow CytometryHumansK562 CellsLeukocytes, MononuclearMiceMice, Inbred NODMice, SCIDAllogeneic hematopoietic stem cell transplantationChronic myeloid leukemiaFlow cytometryGraft-versus-leukemia immunityIn vivo imaging systemNSG miceXenogeneic graft-versus-host disease

Identifiers

PMID40100606

DOI10.1093/ilar.43.4.244

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.